Company Overview
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres across the United States, delivering a comprehensive suite of outpatient medical imaging services to patients and healthcare providers. Operating within the Healthcare sector and specifically the Medical Devices industry, the company functions as a specialized provider of essential diagnostic tools and services required for accurate patient assessment and treatment planning. The enterprise holds a market capitalization of $1.03B, while specific metrics regarding annual revenue and total employee count are not currently disclosed in the available financial data. These valuation figures indicate that the market assigns a significant enterprise value to the company's operational footprint in diagnostic imaging, reflecting investor confidence in its service portfolio which includes magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), X-ray, and ultrasound services. The absence of disclosed employee counts suggests that the company's operational scale is primarily measured through its market valuation and service output rather than traditional headcount metrics in the current reporting period.
Financial Health
The company's financial statements for the trailing twelve months show that revenue, net income, and EBITDA figures are not disclosed in the available data, preventing a direct calculation of the gap between gross revenue and net profitability in this specific reporting window. Consequently, the free cash flow position remains unquantified in the provided facts, which limits the immediate assessment of the company's financial flexibility regarding capital expenditures and debt servicing capabilities. Analysis of the margin structure reveals that the gross margin, operating margin, and profit margin are all reported as 0.0%, indicating that the available data does not reflect positive profitability figures or that these metrics are currently unavailable for standard calculation. This presentation of zero margins alongside missing revenue data suggests a distinct reporting status where traditional profitability metrics have not been realized or disclosed in the current fiscal context. Regarding liquidity and leverage, the available facts do not provide specific figures for total cash or total debt, meaning a comparison of these assets against liabilities cannot be performed to determine if the balance sheet is conservative or leveraged. Similarly, the current ratio is not disclosed, so there is no data available to explain the company's short-term liquidity position or its ability to cover current liabilities with current assets. Furthermore, the return on equity and return on assets metrics are listed as unavailable, which precludes an evaluation of management effectiveness in generating returns from shareholders' equity and total assets based on the current data set.
Valuation Assessment
The valuation profile of Lumexa Imaging Holdings, Inc. includes a forward P/E ratio of 14.75, while the trailing P/E ratio is not available in the provided financial facts. The absence of a trailing P/E figure compared to the existence of a forward P/E implies that the market is pricing the stock based on anticipated future earnings rather than historical performance, suggesting an expectation of an upcoming earnings trajectory that will establish a trailing multiple in future periods. The price-to-book ratio stands at 40.60, a figure that indicates the market is valuing the company at a substantial premium over its tangible book value, potentially reflecting high growth expectations or intangible asset value not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are not disclosed in the available data, limiting the ability to cross-reference these specific multiples against the forward P/E for a comprehensive valuation view. In terms of price volatility and trading range, the stock has a 52-week high of $19.45 and a 52-week low of $9.96. Without a specific current share price provided in the facts, the exact percentage deviation from this range cannot be calculated, but the wide spread between the high and low demonstrates significant price movement over the past year. The beta value is not disclosed, so a precise comparison of the stock's price volatility relative to the broader market index cannot be determined from the available information.
Growth & Income
The revenue growth and earnings growth rates for the year-over-year period are not disclosed in the available facts, preventing a direct comparison to determine if earnings are growing faster or slower than revenue. Because the dividend yield and payout ratio are both listed as unavailable or zero respectively, the company does not currently distribute dividends to shareholders. Instead of paying dividends, the company reinvests its earnings or available capital back into the business to fund operations, expansion, or other growth initiatives rather than distributing cash to investors. The overall growth and income profile is characterized by the lack of disclosed growth rates and the absence of a dividend program, indicating a capital allocation strategy focused on operational reinvestment rather than income generation for current shareholders.